Company intelligence / Profile preview
Appia Bio
Culver City / Los Angeles area, California, United Statesappiabio.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
01
Overview
No published clinical results yet. The company has raised significant funding ($52M Series A) to advance its lead programs toward the clinic, focusing on scalable off-the-shelf allogeneic cell therapies for cancer using their proprietary ACUA platform.
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic cell therapies (off-the-shelf)CAR-iNKT cells (Chimeric Antigen Receptor invariant Natural Killer T cells)HSC-derived cell therapies (from hematopoietic stem cells)TCR gene engineering
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Gilead Sciences/Kite Pharma — collaboration and license agreement to develop HSC-derived allogeneic cell therapies for blood cancers. Deal value up to $875 million plus royalties.
Beyond the preview
Go deeper on Appia Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Appia Bio.